+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Patient Derived Xenograft / PDX Models - Global Strategic Business Report

  • PDF Icon

    Report

  • 310 Pages
  • February 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 4845767
The global market for Patient Derived Xenograft / PDX Models was valued at US$412.3 Million in 2023 and is projected to reach US$1.0 Billion by 2030, growing at a CAGR of 14.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Patient-Derived Xenograft (PDX) Models Market - Key Trends & Drivers Summarized

How Are PDX Models Revolutionizing Cancer Research and Drug Development?

Patient-derived xenograft (PDX) models have emerged as a powerful tool in cancer research and drug development, offering more accurate representations of human tumor biology compared to traditional cell lines and animal models. PDX models are created by implanting human tumor tissues directly into immunodeficient mice, allowing the tumor to grow and be studied in a living organism. This process preserves the genetic and histological characteristics of the original tumor, including its microenvironment and heterogeneity, which are critical for understanding cancer’s behavior and treatment responses. PDX models provide a more realistic platform for testing the efficacy of new cancer therapies, allowing researchers to observe how tumors evolve and react to different drugs in vivo. These models have become essential for precision medicine, enabling the identification of patient-specific treatments and offering hope for improved clinical outcomes. As personalized cancer therapies gain traction, the demand for PDX models continues to rise, significantly impacting oncology research.

Why Is the Pharmaceutical Industry Investing Heavily in PDX Models?

The pharmaceutical and biotechnology industries are increasingly adopting patient-derived xenograft (PDX) models in preclinical studies to enhance the success rate of clinical trials. Traditional in vitro and animal models often fail to accurately predict how a human tumor will respond to a treatment, contributing to the high failure rate of oncology drugs in clinical trials. PDX models, on the other hand, provide a more reliable means of evaluating drug efficacy and toxicity, thus improving the chances of clinical success. Pharmaceutical companies are leveraging PDX models to conduct more efficient drug screening, reduce time to market, and lower the costs associated with drug development. Furthermore, the integration of genomic and transcriptomic data from PDX models allows for the identification of biomarkers that can guide patient selection and stratification in clinical trials. This personalized approach enhances the precision of targeted therapies and immunotherapies, increasing the likelihood of successful treatment outcomes. As the need for more predictive preclinical models grows, the pharmaceutical industry's investment in PDX technology is expected to accelerate.

How Are PDX Models Enhancing Personalized Medicine and Precision Oncology?

PDX models are playing a pivotal role in the advancement of personalized medicine and precision oncology. By maintaining the biological integrity of the original patient tumor, PDX models allow researchers to study tumor-specific drug responses and identify personalized treatment options. This is particularly important in cancers where patient outcomes vary widely depending on genetic mutations and molecular markers. The use of PDX models in preclinical research enables scientists to tailor therapies to individual patients, increasing the likelihood of successful treatment. Additionally, PDX models are being used to develop combination therapies and evaluate resistance mechanisms, offering insights into how tumors may evolve during treatment and relapse. With the rising emphasis on developing therapies that are tailored to the unique genetic profiles of patients, PDX models are becoming indispensable tools for predicting treatment responses, guiding clinical decision-making, and advancing the field of precision oncology.

What Factors Are Driving Growth in the Patient-Derived Xenograft (PDX) Models Market?

The growth in the patient-derived xenograft (PDX) models market is driven by several factors that are reshaping cancer research and drug development. Technological advancements in genetic sequencing and molecular profiling have significantly enhanced the ability to create and analyze PDX models, making them more predictive and valuable in preclinical testing. The increasing focus on precision medicine and personalized cancer therapies is another major driver, as PDX models offer a more accurate and patient-specific platform for evaluating treatment responses. Pharmaceutical companies are adopting PDX models to improve the efficiency of drug development and reduce the high failure rates associated with traditional clinical trials. Furthermore, the rise in cancer incidence worldwide and the growing demand for novel, targeted therapies are fueling the need for advanced preclinical models like PDX. Additionally, collaborations between academic institutions, research organizations, and pharmaceutical companies are accelerating the development and commercialization of PDX platforms, further driving market growth. As the landscape of oncology research continues to evolve, the demand for PDX models is expected to expand, solidifying their role as a cornerstone of cancer research and drug development.

Scope of the Study

The report analyzes the Patient Derived Xenograft / PDX Models market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments:

Model Type (Mice PDX Models, Rat PDX Models); Tumor Type (Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Other Tumor Types); Application (Pre-Clinical Drug Development Application, Biomarker Analysis Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use, Academic & Research Institutes End-Use).

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Mice PDX Models segment, which is expected to reach US$799.3 Million by 2030 with a CAGR of a 14.8%. The Rat PDX Models segment is also set to grow at 12.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $203.8 Million in 2023, and China, forecasted to grow at an impressive 15.4% CAGR to reach $88.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Abnova Corporation, Altogen Labs, Aragen Life Sciences, Biocytogen Pharmaceuticals Co., Ltd., Certis Oncology Solutions and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Patient Derived Xenograft / PDX Models Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Patient Derived Xenograft / PDX Models Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Patient Derived Xenograft / PDX Models Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Some of the 42 major companies featured in this Patient Derived Xenograft / PDX Models market report include:

  • Abnova Corporation
  • Altogen Labs
  • Aragen Life Sciences
  • Biocytogen Pharmaceuticals Co., Ltd.
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories
  • Creative Animodel
  • Crown Bioscience Inc.
  • EPO Berlin-Buch GmbH
  • InnoSer
  • Inotiv, Inc.
  • Oncodesign Services
  • Shanghai Chempartner Co. Ltd.
  • LIDE Shanghai Biotech, Ltd.
  • The Jackson Laboratory
  • Wuxi AppTec
  • Xenopat
  • Xentech

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Rise in Cancer Incidence Fosters Growth in Patient Derived Xenograft / PDX Models Market
Select Cancer Statistics
EXHIBIT 1: Total Number of New Cancer Cases by Type: 2022
EXHIBIT 2: Total Number of Cancer Deaths by Type: 2022
EXHIBIT 3: Cancer Incidence by Region: 2022
EXHIBIT 4: Cancer Mortality by Region: 2022
Evolution & Relevance of PDX Models
Establishing PDX Models
PDX Models: Key Applications
Economic Frontiers: Trends, Trials & Transformations
EXHIBIT 5: In a World Torn by Geopolitical Instability & War, Steadfastness of Global GDP Becomes Increasingly Unpredictable Given the Many Direct and Indirect Economic Repercussions: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025
EXHIBIT 6: All Eyes on Global Inflation, the Main Risk Factor in Global Markets: Global Headline Inflation Rates (In %) for the Years 2019 through 2025
EXHIBIT 7: With Oil Prices Influencing the Rate of inflation, it Remains the Most Watched Commodity in Global Markets: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025
Competitive Scenario
EXHIBIT 8: Patient Derived Xenograft / PDX Models - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for 42 Players Worldwide in 2024 (E)
Global Market Overview and Prospects
Patient-Derived Xenograft (PDX) Models to Gain More Ground & Become a Buzz Market
Delving into Paradigm Segments of Global Patient-Derived Xenograft Model Market
Preclinical Drug Development as Key Application
Patient-Derived Xenograft Model Market on the March with Interplay of Dynamic Factors
Market Drivers
Market Opportunities
Market Restraints
Market Challenges
Developments Trending Big on Global Patient-Derived Xenograft Model Market
EXHIBIT 9: Select Recently Announced Scientific Research PDX Models & Biobanks of Different Cancer Types
Regional Market Analysis
North America Remains at Forefront, while Asia-Pacific Dazzles with Steamy Growth on Global PDX Model Market
Market Outlook
Recent Market Activity
Influencer/Product/Technology Insights
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Patient-Derived Xenograft (PDX) Models Transform Personalized Medicine
EXHIBIT 10: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
PDX Models Paving the Way for Targeted Therapies
The Surge in Investment for Cancer Research to Propel Market Growth
Patient-Derived Xenograft (PDX): A Pulsating Tool in the Cancer Research Arsenal
EXHIBIT 11: Cancer Research Funding Scenario (2024): Funding Investments & Grants by Major Entities
Harnessing the Power of OMICs Technologies Through PDX Models
Advancing Predictive Biomarker Discovery with PDX Models
Increased Focus on Drug Resistance Studies in Oncology Spurs Demand for Patient-Derived Xenograft Models
PDX Models Advance the Evaluation of Treatment Efficacy and Toxicity
Technological Advancements Driving Innovation in PDX Models
The Intersection of PDX Models and 3D Printing
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Patient Derived Xenograft / PDX Models Market Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World 7-Year Perspective for Patient Derived Xenograft / PDX Models by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Mice PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 5: World 7-Year Perspective for Mice PDX Models by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 6: World Recent Past, Current & Future Analysis for Rat PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 7: World 7-Year Perspective for Rat PDX Models by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World 7-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 11: World 7-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 12: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 13: World 7-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World 7-Year Perspective for Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Other Tumor Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 17: World 7-Year Perspective for Other Tumor Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 18: World Recent Past, Current & Future Analysis for Pre-Clinical Drug Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 19: World 7-Year Perspective for Pre-Clinical Drug Development Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Biomarker Analysis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 21: World 7-Year Perspective for Biomarker Analysis Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 23: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 24: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 25: World 7-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for CROs / CDMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 27: World 7-Year Perspective for CROs / CDMOs End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 29: World 7-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Market Analytics
CANADAJAPAN
CHINA
Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Market Analytics
EUROPE
Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Market Analytics
FRANCEGERMANYITALYUNITED KINGDOMREST OF EUROPE
ASIA-PACIFIC
Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Market Analytics
REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abnova Corporation
  • Altogen Labs
  • Aragen Life Sciences
  • Biocytogen Pharmaceuticals Co., Ltd.
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories
  • Creative Animodel
  • Crown Bioscience Inc.
  • EPO Berlin-Buch GmbH
  • InnoSer
  • Inotiv, Inc.
  • Oncodesign Services
  • Shanghai Chempartner Co. Ltd.
  • LIDE Shanghai Biotech, Ltd.
  • The Jackson Laboratory
  • Wuxi AppTec
  • Xenopat
  • Xentech